CN115361959A - 用于使用间充质谱系前体或干细胞治疗过度炎症的方法 - Google Patents

用于使用间充质谱系前体或干细胞治疗过度炎症的方法 Download PDF

Info

Publication number
CN115361959A
CN115361959A CN202180027057.9A CN202180027057A CN115361959A CN 115361959 A CN115361959 A CN 115361959A CN 202180027057 A CN202180027057 A CN 202180027057A CN 115361959 A CN115361959 A CN 115361959A
Authority
CN
China
Prior art keywords
subject
cells
stem cells
mesenchymal lineage
mlpscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027057.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·伊茨库
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901052A external-priority patent/AU2020901052A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CN115361959A publication Critical patent/CN115361959A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180027057.9A 2020-04-03 2021-04-01 用于使用间充质谱系前体或干细胞治疗过度炎症的方法 Pending CN115361959A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
AU2020901052 2020-04-03
AU2020901052A AU2020901052A0 (en) 2020-04-03 Method for treating hyperinflammation which comprise administering mesenchymal lineage precursor or stem cells
AU2020901124 2020-04-08
AU2020901124A AU2020901124A0 (en) 2020-04-08 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312A AU2020902312A0 (en) 2020-07-06 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312 2020-07-06
AU2020902425A AU2020902425A0 (en) 2020-07-14 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902425 2020-07-14
AU2020903041 2020-08-25
AU2020903041A AU2020903041A0 (en) 2020-08-25 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903694 2020-10-12
AU2020903694A AU2020903694A0 (en) 2020-10-12 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020904312 2020-11-23
AU2020904312A AU2020904312A0 (en) 2020-11-23 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
PCT/EP2021/058683 WO2021198454A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
CN115361959A true CN115361959A (zh) 2022-11-18

Family

ID=77927537

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027057.9A Pending CN115361959A (zh) 2020-04-03 2021-04-01 用于使用间充质谱系前体或干细胞治疗过度炎症的方法

Country Status (9)

Country Link
US (1) US20230165904A1 (https=)
EP (1) EP4125957A1 (https=)
JP (1) JP2023520233A (https=)
KR (1) KR20220164741A (https=)
CN (1) CN115361959A (https=)
AU (1) AU2021245369A1 (https=)
BR (1) BR112022020042A2 (https=)
CA (1) CA3173216A1 (https=)
WO (1) WO2021198454A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
US12067745B2 (en) 2022-09-27 2024-08-20 Kla Corporation Image pre-processing for overlay metrology using decomposition techniques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
CN110101873A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用il-10转基因的干细胞治疗ards的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
JP6173157B2 (ja) * 2013-10-02 2017-08-02 日本製薬株式会社 Ｉｌ−１７産生抑制組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
CN110101873A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用il-10转基因的干细胞治疗ards的方法

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHAOLIN HUANG等: "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", LANCET, vol. 395, 24 January 2020 (2020-01-24), pages 497 - 506, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5 *
ERIKA POGGIALI等: "Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?", EUROPEAN JOURNAL OF CASE REPORTS IN INTERNAL MEDICINE, 8 April 2020 (2020-04-08), pages 1 - 7 *
JULIE TOUBIANA等: "Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study", THE BMJ, vol. 369, 3 June 2020 (2020-06-03), pages 1 - 7, XP009532517, DOI: 10.1136/bmj.m2094 *
LI-TZU WANG等: "Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials", JOURNAL OF BIOMEDICAL SCIENCE, vol. 23, 4 November 2016 (2016-11-04), pages 1 - 13 *
MESOBLAST: "MESOBLAST TO EVALUATE ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE", pages 1, XP055810621, Retrieved from the Internet <URL:http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc> DOI: 10.1101/2020.02.17.20024166 *
SAIRAM ATLURI等: "Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy In Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use", PAIN PHYSICIAN, vol. 23, 1 March 2020 (2020-03-01), pages 71 - 83 *
南模生物: "COVID-19新冠肺炎之细胞因子风暴", Retrieved from the Internet <URL:https://zhuanlan.zhihu.com/p/122236342> *
古利明等: "人脐带间充质干细胞联合抗病毒等方法治疗新型冠状病毒肺炎", 昆明医科大学学报, no. 03, 15 March 2020 (2020-03-15), pages 102 - 106 *
徐亦鸣等: "2019冠状病毒病(COVID-19)患者出凝血功能障碍的研究进展", 浙江大学学报, 22 May 2020 (2020-05-22), pages 340 - 346 *
梅恒等: "新型冠状病毒肺炎（COVID-19）患者出凝血功能障碍病因分析及诊治策略", 中华血液学杂志, vol. 41, no. 3, 31 March 2020 (2020-03-31), pages 185 - 191 *
鞠秀丽: "间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展", 山东大学学报(医学版), no. 03, 31 March 2020 (2020-03-31), pages 38 - 43 *
飞扬: "细胞因子风暴—新冠的致病机制", Retrieved from the Internet <URL:https://zhuanlan.zhihu.com/p/107833594> *

Also Published As

Publication number Publication date
CA3173216A1 (en) 2021-10-07
KR20220164741A (ko) 2022-12-13
BR112022020042A2 (pt) 2022-11-22
JP2023520233A (ja) 2023-05-16
AU2021245369A1 (en) 2022-11-03
US20230165904A1 (en) 2023-06-01
WO2021198454A1 (en) 2021-10-07
EP4125957A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
CN115361959A (zh) 用于使用间充质谱系前体或干细胞治疗过度炎症的方法
CN115361960A (zh) 用于治疗慢性移植物抗宿主病的方法
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
WO2023119239A1 (en) Method of treating severe graft versus host disease
CN117337184A (zh) 使用间充质谱系前体细胞或干细胞治疗急性呼吸窘迫综合征(ards)的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination